- Home
- FICO vs CANF Comparison
FICO vs CANF Comparison
Compare FICO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FICO | CANF |
|---|---|---|
| Founded | 1956 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7B | 4.7M |
| IPO Year | 1995 | 2011 |
Fundamental Metrics
Financial Performance| Metric | FICO | CANF |
|---|---|---|
| Price | $1,058.40 | $3.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | $1,868.33 | ★ $9,750.00 |
| AVG Volume (30 Days) | 355.4K | ★ 615.0K |
| Earning Date | 04-28-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 6.61 | N/A |
| Revenue | ★ $1,032,475,000.00 | N/A |
| Revenue This Year | $27.33 | $2,715,455.50 |
| Revenue Next Year | $17.20 | $101.06 |
| P/E Ratio | $160.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $969.32 | $0.17 |
| 52 Week High | $2,217.60 | $10.40 |
Technical Indicators
Market Signals| Indicator | FICO | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 37.08 |
| Support Level | $969.32 | $0.59 |
| Resistance Level | $1,829.71 | $4.74 |
| Average True Range (ATR) | 52.61 | 0.19 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 34.12 | 15.66 |
Price Performance
Historical ComparisonAbout FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.